Brokerages Set Solventum Corporation (NYSE:SOLV) Target Price at $87.00

Shares of Solventum Corporation (NYSE:SOLV) have received an average rating of “Hold” from the thirteen analysts that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and four have issued a buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $87.00.

SOLV has been the topic of a number of recent analyst reports. Jefferies Financial Group assumed coverage on shares of Solventum in a report on Thursday, September 11th. They set a “hold” rating and a $80.00 price target on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of Solventum in a research note on Thursday, October 30th. Wells Fargo & Company raised their target price on Solventum from $79.00 to $82.00 and gave the company an “equal weight” rating in a research report on Monday, September 15th. UBS Group restated a “neutral” rating on shares of Solventum in a research note on Friday, November 21st. Finally, Piper Sandler reiterated an “overweight” rating on shares of Solventum in a research report on Wednesday, December 17th.

Solventum Trading Up 0.3%

Solventum stock opened at $80.45 on Friday. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.14 and a current ratio of 1.50. The stock has a market cap of $13.95 billion, a PE ratio of 9.27, a price-to-earnings-growth ratio of 8.49 and a beta of 0.25. The stock has a 50-day moving average of $77.73 and a two-hundred day moving average of $74.87. Solventum has a one year low of $60.70 and a one year high of $88.20.

Solventum (NYSE:SOLV) last released its earnings results on Thursday, November 6th. The company reported $1.50 earnings per share for the quarter, topping the consensus estimate of $1.43 by $0.07. The company had revenue of $2.10 billion for the quarter, compared to the consensus estimate of $2.05 billion. Solventum had a net margin of 18.13% and a return on equity of 28.01%. Solventum’s revenue was up .7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.64 EPS. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. On average, research analysts anticipate that Solventum will post 6.58 EPS for the current fiscal year.

Solventum announced that its board has approved a share repurchase program on Thursday, November 20th that authorizes the company to buyback $1.00 billion in shares. This buyback authorization authorizes the company to reacquire up to 7.5% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s leadership believes its shares are undervalued.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Allworth Financial LP raised its stake in Solventum by 2.8% during the third quarter. Allworth Financial LP now owns 4,788 shares of the company’s stock worth $350,000 after purchasing an additional 129 shares during the period. CIBC Private Wealth Group LLC increased its holdings in shares of Solventum by 0.5% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 24,710 shares of the company’s stock worth $1,804,000 after buying an additional 134 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd raised its position in shares of Solventum by 0.7% during the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,778 shares of the company’s stock valued at $1,500,000 after buying an additional 140 shares during the period. BOKF NA lifted its holdings in Solventum by 6.9% in the third quarter. BOKF NA now owns 2,193 shares of the company’s stock valued at $160,000 after acquiring an additional 141 shares during the last quarter. Finally, CHICAGO TRUST Co NA lifted its holdings in Solventum by 3.0% in the third quarter. CHICAGO TRUST Co NA now owns 5,188 shares of the company’s stock valued at $379,000 after acquiring an additional 150 shares during the last quarter.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.